DLL3xSEZ6 bsADC
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 03, 2025
Bispecific antibody-drug conjugates targeting DLL3×B7-H3 and DLL3×SEZ6 demonstrate potent anti-tumor activity in preclinical models of small-cell lung cancer
(SITC 2025)
- "Despite the approval of tarlatamab and ongoing development of DLL3- or B7-H3-targeted ADCs, tumor relapse and heterogeneity in target expression continue to pose challenges...We used in vitro internalization activity, in vivo anti-tumor efficacy in SCLC CDX or PDX models, and developability screening as primary selection criteria.Results The DLL3×B7-H3 bsAb showed stronger internalization in double positive cell lines than the parental monovalent arms and outperformed the naked antibodies of DS-7300 and rovalpituzumab (Rova)...The DLL3×SEZ6 bsADC demonstrated comparable efficacy to benchmark with same payload and showed more potent anti-tumor efficacy than parental monovalent ADCs in SCLC CDX models.DLL3×B7-H3 and DLL3×SEZ6 bsAbs exhibited excellent stability under stress conditions, suggesting them as promising candidates for CMC development.Conclusions DLL3×B7-H3 and DLL3×SEZ6 bsADCs represent two novel and complementary strategies for..."
Preclinical • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276 • DLL3 • SEZ6 • TOP1
March 26, 2025
Preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models
(AACR 2025)
- "Tarlatamab, a T cell engager targeting DLL3, was recently approved for SCLC. In vivo, the bsADC exhibited robust anti-tumor efficacy in SCLC xenograft models. In summary, our DLL3xSEZ6 bsADC showed promising in vitro and in vivo preclinical activities with first-in-class potential for treatment of SCLC."
Preclinical • Brain Cancer • CNS Tumor • Endocrine Cancer • Glioblastoma • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • SEZ6 • TOP1
1 to 2
Of
2
Go to page
1